9-ING-41 in Patients With Advanced Cancers
Trial details
- Registry ID
- NCT03678883
- Phase
- Phase 2
The FDA approved Lomustine (CCNU) on 4 Aug 1976.
Drug identity checked against registry records
Also recorded as CCNU; CeeNU; Gleostine; Lomustine Capsules
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| 9-ING-41 in Patients With Advanced CancersNCT03678883 | ACTU | Phase 2 | Active not recruiting | 2026-06Estimated |
| A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma MultiformeNCT04762069 | CNSP | Phase 2 | Active not recruiting | 2026-04-27Estimated |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 1976-08-04Day | Lomustine | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "NDA017588", "applicant_as_listed_by_fda": "AZURITY", "brand_names": ["GLEOSTINE"], "active_ingredients": ["LOMUSTINE"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "19760804", "matched_on": "drug name equals FDA sole active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |